New Clinical Trial Will Test Cancer Drug as Alzheimer’s Treatment


Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF, says: “The ADDF is proud to support a clinical trial that holds such promise for Alzheimer’s patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer’s.”

Experimental Imaging Agent Reveals Concussion-Linked Brain Disease in Living Brain


Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death

Vivreon Biosciences Awarded Grant to Advance Drug Program Targeting Neuroinflammation


Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF) to develop compounds that targets brain inflammation in Alzheimer's disease.

$1.7 Million Grant Supports Promising Drug That Targets Cannabinoid Receptor


With a $1.7 million award from the ADDF, a new biotech created by Cleveland Clinic Innovations is developing a novel drug that reduces inflammation in the brain by targeting a cannabinoid receptor.

Dr. D. Martin Watterson Wins Second Melvin R. Goodes Prize


Dr. Watterson Has Identified a Number of New Classes of Central Nervous System Drugs 

Three New Grants Support Promising Treatments for Alzheimer’s Disease


The ADDF awarded three new grants in July and August for potential new treatments for Alzheimer's and other dementias. 

Panel of Experts Calls for Comparative Effectiveness Research


With Better Evidence, Routine Medical Decisions Could Help Prevent Dementia

Five New Grants Fund Promising Treatments & Biomarkers


The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.

Lauder and Newhouse Families Announce New Initiative to Find Treatments for Frontotemporal Dementia


The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have jointly committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade. And it has the potential to advance treatments for other neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s.

Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development


The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression. The grants include funding for four novel programs with the potential to treat a range of diseases, including Alzheimer’s, Huntington’s, and Parkinson’s.